

REVIEW

DOI: 10.4274/tjps.galenos.2022.69922

THE ROLE OF PROINFLAMMATORY MEDIATOR INTERLEUKIN-32 IN OSTEOCLAST DIFFERENTIATION

Short title: Osteoclast activation Therapeutic techniques and processes

Taha Nazir¹, Nida Taha¹, Azharul Islam², Ishtiaq Rabbi³, Pervaiz Akhter Shah⁴

1. Microbiology and Molecular Biology Research Group, Advanced Multiple Incorporation, Mississauga ON Canada.
2. Scientist, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
3. Consultant Pharmacist, Al Mushrif, Airport Road Abudabhi UAE.
4. University College of Pharmacy, University of the Punjab, Lahore, Pakistan.

Corresponding Author Information

PhD Taha Nazir

taha@advancedmultiple.ca

+16475260885

<https://orcid.org/0000-0002-5308-6798>

26.10.2021

31.03.2022

05.04.2022

Abstract:

The recently explained cytokine which is produced after the stimulation of IFN- γ , IL-2 and IL-18 is Interleukin-32 (IL-32). This cytokine has proinflammatory IFN- γ , IL-2 and IL-18 are Interleukin-32 (IL-32) mediator's properties that are generally entailed in many diseases, including infections, cancer and chronic inflammation. After the initial statement in 2005, it promoted the osteoclast precursor's differentiation into TRAcP plus VNR plus multinucleated cells which express explicit osteoclast indicators. Furthermore, the loss of bone resorption might be accredited because of the collapse of the multinucleated cells which are produced of the reaction to IL-32 to direct Factoring that is ultimately essential for the attachment of the cells for bone resorption. Thus, in conclusion, the proinflammatory mediator interleukin-32 has important and indirect role to regulate the osteoclast differentiation. In bone disorder's pathophysiology, the critical role of IL-32 needs more scientific evidences to develop a rational treatment protocol. IL-32 can become a potent mediator of active osteoclast generation in the presence of RANKL. This novel cytokine can introduce more favorable conditions for osteoclastogenesis in the rheumatic arthritis by increasing the RANKL and Osteoprotegerin ratio in fibroblast-like synoviocytes.

Keywords Interleukin-32, Cytokines, Osteoclast, Proinflammatory.

Introduction

In 1992, the focused molecule in this review was first reported. In that report, reported that there is a protein which was called NK4, which is extremely articulated in activated-T and NK cells. This protein was rapidly up-regulated after the stimulation by PHA, a lectin that is primary for activation of T-cells in human PBMCs. In 2005, that NK4 was found as one of the most up-regulated genes utilizing microarray expertise and Interleukin-18 receptive cell unit¹. After that, two others innovative integrins of Interleukin-32 were established in Interleukin-32 mRNA transcript i.e. Interleukin-32 ϵ and Interleukin-32 ζ , but IL-32 β appears to be superabundant². The IL-32 different isoforms produce by splicing of isoform IL-32 γ pre-mRNA. Many reports explained that IL-32 different transcripts present both in vitro³ and in vivo⁴. Its remnants that by which means Interleukin-32 γ mRNA copies are replicated and incomplete body cells process is same. Keeping in mind the cell stimulation and cell demise, IL-32 γ is the utmost leading IL-32 isoform, explains why IL-32 γ explodes into less injurious IL-32 isoforms, such as IL-32 β and α ⁴. The IL-32 isoforms differential potency was explained in many reports⁶, however basis of potency differences between the isoforms remains unknown. In the explanation of this process, the variance between the extent of the integrins from 14.9 kDa (Interleukin-32 α) to 26.7 kDa (IL-32 γ), so that isoform's tertian assembly can be explained.⁵

Expression and regulation of Osteoclast

Inlacunarily bone resorption is the specific function of multinucleated Osteoclasts cells which originate from the hematopoietic lineage (CFU-GM)⁶. The presence of KB ligand nuclear factor by receptor activator and colony-stimulating factor of macrophage is compulsory of the discrepancy of osteoclast by circulating hematopoietic predecessors⁷.

The Site triggers for nuclear feature kB ligand (RANKL) is part of the Tumor necrosis factor (TNF) which is present on T cells, osteoblasts and binds with its receptor, receptor activator for nuclear factor-kB(RANK), which are articulated on precursors of osteoclast⁸. Activation of different intracellular pathways like MAP kinase, NFATc1, Akt and NF-Kb pathways has been described as the result of RANK binding with RANKL. Osteoprotegerin (OPG) which acts like RANKL decoy receptor causes the stimulation of resorbing activity by osteoclast and blocks the differentiation of osteoclast-mediated by RANKL^{9,10}. Although RANKL is one of the critical factors for osteoclastogenesis, several pro-inflammatory cytokines like IL-8, TNF-alpha and LIGHT proves the RANKL independent mechanisms¹¹.

Multiple cell interaction evolute of Rheumatoid Arthritis

Approximately 0.5% adult population is affected by Rheumatoid Arthritis (RA) worldwide, which is the main reason for disability. Rheumatoid Arthritis can be defined as an enduring inflammatory disease in which advanced joint annihilation take place including articular cartilage damage which is caused by inflammatory cells that are chondrocytes and activated synovial fibroblasts. The factors which are produced in the affected joints and a broad array of cytokines control the arthritis evolution. The anti-inflammatory cytokines i.e. IL-10 and TGF-b are exceeded by pro-inflammatory molecules level particularly monokines TNF-a and IL-1b¹². The importance of macrophages and cytokines production in Rheumatoid Arthritis is clearly explained by Biological therapies which were directing TNF-a, targeting IL-1 and IL-6¹³. However, these treatments when given repeatedly, achieve only brief clinical responses. Furthermore, approximately 40 % of patients with 50% response reach the American College of Rheumatology (ACR)¹⁴.

FLS cultures

In sub confluence (70 %) FLS were grown which contain complete medium i.e. 10% fetal calf serum in addition to RPMI 1640, 500 units/mL of penicillin and 100 lg/mL streptomycin in a culture flask. From the 3rd passage, all the experiments were performed by using FLS. At this time there were 0-2% contaminating macrophages, natural killer cells, and lymphocytes.¹⁵

RNA preparation

For eliminating genomic DNA contamination DNase I are treated with entire RNA which is obtained after culturing cells in RLT® RNA extraction buffer (Rneasy, Qiagen kit). By using RNA kit 6000 Lab Chip (Agilent Technologies) and a Bio-analyzer 2100 the unity and clarity of the entire RNA, and cRNA, were analyzed. The ratio of total RNA with 28S/18S > 1.7 was only used. Through NanoDrop (NanoDrop Technologies) concentrations of cRNA were calculated.¹⁶

cRNA production and Probe range hybridization

As per the producer's protocol (GeneChip® Expression Analysis Technical Manual, Rev.5, Affymetrix Inc., 2004) through the GeneChip Expression 3' Amplification One-Cycle Target Tagging and Controlling Components, cRNA preparation was carried out with 3 lg of entire RNA, then combine with the human genetic material U133 Plus 2.0. Briefly, in an initial-strand cDNA composite reaction utilizing a T7-Oligo(dT) protagonist primer, the entire RNA was initially inverse transcribed. Then the double-stranded cDNA was washed in second-strand cDNA synthesis that is facilitated by RNase H and is active as a prototype in the *in vitro* transcript reaction (IVT)¹⁷. In the presence of a biotinylated nucleotide analogue and T7 RNA polymerase, IVT reaction was performed. Then biotinylated cRNA marks were washed up, broken into pieces, and hybridized with GeneChip expression arrays. Then using Affymetrix fluidics station 450 (Affymetrix, Inc.) it is washed and stained and then the reviewed ranges are perused into the Affymetrix GeneChip Scanner 3000.

FLS Gene express model

Utilizing the GeneChip Human Genome U133A Plus 2.0 (Affymetrix, Santa Clara, CA, USA), microarrays evaluated the genetic appearance profiles. Gene expression was evaluated by cultivated FLS obtained of 8 and 9 patients of RA and OA respectively. For further analysis, outcomes from 241 investigations on behalf of 171 different cytokines and their particular receptors. The selected genes whose appearance was diverse and approximately 1.6 times among the FLS of two disorders and had a p-value of up to 0.05.¹⁸


Microarray scrutiny

In Gene Spring, the stated raw details were computed with the GC-RMA File preprocessor. Specific probe data stored in Affymetrix CEL files were used by the GC-RMA algorithm. With Genespring 7.2 raw data processing, data analysis and normalization were done. The value of each gene was set to 1 in different conditions and it was ensured by using GeneSpring normalization ("Per Gene: Normalize the median"). It means that those genes which do not alter in different conditions have a value of 1 for Normalization expression that allow easy detection of distinctive expressed genes visually.

The absence of sRANKL Interleukin-32 inspires the discrepancy of supporter PBMCs into multinucleated TRAcP+, VNR+ cells

Now it is thought that M-CSF and RANKL are two crucial aspects that are supplied by osteoclasts which are vital for the maturation and discrepancy of precursors of osteoclast¹⁹. Whereas, the mice that are defective by M-CSF (op/op) exhibit an osteopetrotic appearance that could be voluntarily converse with time and suggest that there is a substitute osteoclastic trail exists²².

Lacking M-CSF, Vascular endothelial growth factor (VEGF), Hepatocyte growth factor (HGF) and Flt3 ligand all have revealed support to osteoclast creation²¹. Moreover, the mice demonstrate an osteopetrotic appearance triggered by a whole loss of osteoclast in their bones having a deficiency of either RANKL or its receptor RANK²². If there are no osteoclasts detected in bone of the mice that are flawed in RANKL or RANK, it might not happen due to total disaster of osteoclastogenesis. RANKL as a significant and endurance aspect for modified osteoclasts²³ and in the mice deficient with RANKL or RANK, the observed phenotype can be explained by the idea that differentiation is diminished osteoclast superimposed on summarized lifecycle²⁴. As such, in the existence of a large amount of osteoprotegerin that is an inhibitor of interactions of RANKL-RANK, it has been reported that a substitute RANKL-independent pathway (e.g. LIGHT, TGF β and TNF- α) support osteoclastogenesis²⁵. The ground aspect of the osteoimmunology explained that T-cells which are activated straight regulate bone resorption and osteoclastogenesis²⁶, and T cell products i.e. IL-17, TWEAK, GM-CSF and IFN- γ , which can modulate the establishment of osteoclast²⁷. This existing study pursued to find out the part of IL-32, having the representation of pro-inflammatory cytokine and participate in an assortment of inflammatory syndromes by osteoclast activation and differentiation.



Bone Resorption ← F-acting Ring

Figure 1. The Graphic illustration of downriver trails triggered by RANKL. Inconsistency detected in RANKL signaling trails; increased ERK1/2 activation may lead to the activation of unlike downriver goals which in fact can subsidize the incapacity of cells to expose F-actin ring.




Figure 2. The Graphic illustration of downriver trails triggered by Interleukin-32. The inconsistency detected among Interleukin-32; Akt activation by IL-32 may lead to the activation of unlike downriver goals which in fact can subsidize the incapacity of cells to expose F-actin ring and resorb in reaction to Interleukin-32.

Tumor Necrosis factor and osteoclast activation

It has been described that Tumor necrosis factor receptor-associated factor 6 (TRAF6) is imperative for osteoclast stimulation, i.e. lacunar bone resorption and there is a composite part of IFN- γ in osteoclastogenesis. They show that strong reluctance of RANKL-induced activation occurs due to fast degradation of TRAF6 by IFN- γ . Therefore, we hypothesized that due to TRAF-6 degradation the Interleukin-32 single or in amalgamation with soluble RANKL show inhibitory outcome. However, we found and were surprised that TRAF6 is not destroyed but is

overexposed when treated with IL-32 related to RANKL. Recently, Gao et al. have shown IFN- γ shows a “direct” anti-resorptive outcome by reducing the distinction of osteoclast. Therefore, by stimulating T-cells IFN- γ can act “indirectly” as a pro-resorptive feature to direct RANKL and TNF- α ²⁹. In this current study, we utilize PBMCs as a basis of pioneers of osteoclast and significantly cells were cleansed completely to abolish non-adherent cells (B- & T-cells), its reasonable that few T-cells might be existing in the culture and donated to osteoclastogenesis ³⁰. This supposition is also strengthened by indication which explains that the decrease in size and number of multinucleated cells that are newly-synthesised due to excessive accumulation of OPG to the IL-32-treated cultures.

Therapeutic technique or process

It is suggested that osteoclast differentiation was induced by IL-32 is somewhat autonomous of the RANK/RANKL pathway. Though the freeing of pro-inflammatory mediators that were increased by IL-32 have a positive influence on osteoclastogenesis, it had a straight inhibitor consequence in vitro osteoclast instigation and it cannot induce these recently-prepared multinucleated cells activation into bone-resorbing osteoclasts ³¹. It is important to notice that Interleukin-32 has a straight influence over further cell types i.e. epithelial cells, natural killer cells, T-cells and monocytes. Downstream pathways are not fully interpreted that involved in osteoclasts in return to IL-32. The NF- κ B and JNK trails activation are severely increased by PBMCs handlings of M-CSF/RANKL or M-CSF/IL-32 compared to cultures that are treated with M-CSF. However, the Akt pathways activation appeared more complex. The Akt pathways are strongly activated by M-CSF/IL-32 or M-CSF treatments compared to M-CSF/RANKL.

Conclusion

In conclusion, the proinflammatory mediator interleukin-32 has important and indirect role to regulate the osteoclast differentiation. In bone disorder's pathophysiology, the critical role of IL-32 needs more scientific evidences to develop a rational treatment protocol. IL-32 can become a potent mediator of active osteoclast generation in the presence of RANKL. This novel cytokine can introduce more favorable conditions for osteoclastogenesis in the rheumatic arthritis by increasing the RANKL and Osteoprotegerin ratio in fibroblast-like synoviocytes.

References

1. Dahl CA, Schall RP, He HL, Cairns JS (1992) Identification of a novel gene expressed in activated natural killer cells and T cells. *J Immunol* 148:597–603
2. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA (2005) Interleukin-32: a cytokine and inducer of TNF α . *Immunity* 22:131–142
3. Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, Izuhara K (2006) Involvement of IL-32 in activation-induced cell death in T cells. *Int Immunol* 18:233–240
4. Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten LA (2011) Inflammation-dependent secretion and splicing of IL-32 $\{\gamma\}$ in rheumatoid arthritis. *Proc Natl Acad Sci USA* 108:4962–4967
5. Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LA (2012) Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. *Cytokine* 60:321–327
6. Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LA (2012) IL-32 contains a typical alpha-helix bundle structure that resembles the focal adhesion targeting region of focal adhesion kinase-1. *J Biol Chem* 287:5733–5743

7. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, Choi WS, Kim BK, Lee CK, Yoon DY, Kim SJ, Kim SH (2008) Identification of the most active interleukin-32 isoform. *Immunology* 126:535–542
8. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. *Nature* 423: 337–342.
9. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, et al. (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. *ProcNatlAcadSci U S A* 87: 7260–7264.
10. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA (1996) The human osteoclast precursor circulates in the monocyte fraction. *Endocrinology* 137: 4058–4060.
11. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, et al. (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *J Bone Miner Res* 15: 2–12.
12. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 93: 165–176.
13. Quinn JM, Elliott J, Gillespie MT, Martin TJ (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. *Endocrinology* 139: 4424–4427.
14. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. *ProcNatlAcadSci U S A* 96: 3540–3545.
15. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, et al. (1998) RANK is the essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis. *Biochim Biophys Res Commun* 253: 395–400.
16. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *ProcNatlAcadSci U S A* 95: 3597–3602.
17. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 89: 309–319.
18. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, et al. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. *Endocrinology* 139: 1329–1337.
19. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, et al. (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. *Bone* 33:28–37.
20. Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, et al. (2006) LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. *Curr Rheumatol Rep* 2002; 4: 208.
21. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. *Arthritis Rheum* 1990; 33: 305.
22. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumour necrosis factor-alpha in rheumatoid arthritis. *Arthritis Rheum* 1995; 38: 151.

23. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, *et al.* Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-alpha (cA2) *versus* placebo in rheumatoid arthritis. *Lancet* 1994; 344: 1105.
24. Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM. Early *versus* delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. *Am J Med* 2001; 111: 446.
25. Goekoop YP, Allaart CF, Breedveld FC, Dijkmans BA. Combination therapy in rheumatoid arthritis. *Curr Opin Rheumatol* 2001; 13: 177.
26. Neumann E, Gay RE, Gay S, Muller-Ladner U. Functional genomics of fibroblasts. *Curr Opin Rheumatol* 2004; 16: 238.
30. Begg SK, Bertoncello I (1993) The hematopoietic deficiencies in osteopetrotic (op/op) mice are not permanent, but progressively correct with age. *Exp Hematol* 21: 493–495.
27. Begg SK, Radley JM, Pollard JW, Chisholm OT, Stanley ER, *et al.* (1993) Delayed hematopoietic development in osteopetrotic (op/op) mice. *J Exp Med* 177: 237–242.
28. Mabileau G, Sabokbar A (2009) Interleukin-32 Promotes Osteoclast Differentiation but Not Osteoclast Activation. *PLoS ONE* 4(1): e4173.
<https://doi.org/10.1371/journal.pone.0004173>
29. Felix R, Cecchini MG, Fleisch H (1990) Macrophage colony-stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. *Endocrinology* 127: 2592–2594.
30. Hasanzadeh A, Alamdaran M, Ahmadi S, *et al.* Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies. *J Control Release*. 2021; 336: 354–374.
doi:10.1016/j.jconrel.2021.06.036
31. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, *et al.* Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. *Clin Microbiol Rev*. 2021; 34(3): e00228–20. Published 2021 May 12. doi:10.1128/CMR.00228-20